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Abstract Individual genomics has arrived, personal deci-
sions to make use of it are a new reality. What are the
implications for the patient–physician relationship? In this
article we address three factors that call the traditional con-
cept of confidentiality into question. First, the illusion of
absolute data safety, as shown by medical informatics.
Second, data sharing as a standard practice in genomics
research. Comprehensive data sets are widely accessible.
Third, genotyping has become a service that is directly
available to consumers. The availability and accessibility of
personal health data strongly suggest that the roles in the
clinical encounter need to be remodeled. The old ideal of
physicians as keepers of confidential information is out-
stripped by the reality of individuals who decide themselves
about the way of using their data.
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It used to be the pharmaceutical industry approaching you,
seeking probands for clinical trials among your patients,
and it used to be researchers from academia seeking sub-
jects for biomedical and social sciences’ studies, and
recently, it could be a population biobank project notifying
you of your patient’s enrollment and her authorization to
access her medical records that you are keeping.
Today, it may happen that you are approached by one of
your own patients, that you have been treating for years,
asking you to make the data from her medical record
available, as she intends to contribute these to an open
individual genomics project that collects comprehensive
genotype and phenotype data.
Individual genomics is there, personal decisions to make
use of it are a new reality (Editorial 2008). As a doctor,
what should you do?
There are the legal issues surrounding the ownership of
medical data that in many countries resides with the
patient. But how about that other part of your relationship
with your patient—the issues of mutual trust, confidenti-
ality, and protection of privacy?
The combination of health-information altruism (Kohane
and Altman 2005) and self-management by individuals of
their medical data beyond the assumedly safe domains of the
physician’s office and the approved clinical trial seems to
undermine the traditional ideal of Hippocratic confidential-
ity. Many physicians will find the request like that of the
patient mentioned above, utterly disturbing. Besides, com-
plying with it may be quite time consuming. We will argue
that the traditional Hippocratic ideal has in fact been super-
seded quite a long time already.
In practice, one-to-one strict confidentiality between doctor
and patient is the exception rather than the rule, as the clinical
encounter will always include third parties as well. In
research, by industry-based or academic researchers, the
promise of confidentiality often constitutes a key condition for
consent. It is assumed that this promise can be fulfilled through
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measures of data protection. However, it becomes ever more
obvious that absolute data security does not exist. Ethical and
legal frameworks for the conduct of human subjects research
must take into account that strict confidentiality is not a
promise that can be delivered upon. We will give three
examples of factors that call the widely held concept of con-
fidentiality in the medical context into question.
First, the flaws in the strategies and the tools used to
protect identity and information content of participants in
research.
In the past decades comprehensive regulatory frame-
works have been established for the protection of personal
data. Guidelines for research protocols pay a great deal of
attention to describing different modes of coding—e.g.,
single coded, double coded, and anonymized—in order to
ensure the separation of individual identity from information
content in data sets. Both in clinical trials and in epidemio-
logical research there has been a strong focus on control of
the keeper of the key of the code and on conditions for access,
stating under what circumstances the key may be released.
The normative framework of ethics and law has addressed
exactly this: the actors and the rules. Providing guidance to
those conducting research is among the core business of
normative ethics and this involvement is to a large extent
institutionalized in form of committees, advisory groups,
oversight bodies, and the like. In the review process rela-
tively little attention has been paid to the quality of the keys:
how reliable are they? Research in medical informatics and
statistics has shown that security is often illusory, discussion
with patients and research subjects of data protection should
acknowledge this (Malin 2005).
Second, the practice of data sharing leads to a further
distortion of the ideal image of confidentiality.
Large-scale genomics research confronts us with studies
using increasingly comprehensive genotype and phenotype
data sets that are being shared among researchers and that
often are publicly accessible. Moreover, DNA is an iden-
tifier in itself. In this situation, the keepers of the keys to
individual identity are applying old rules to new cases.
Transporting the traditional idea of confidentiality into the
protocols of large-scale genomics research and biobanks, is
misleading. The accessibility of data in a databank will
become the endpoint of a chain of unsustainable promises
of privacy and confidentiality that once started with the
Hippocratic ideal in mind, in a doctor’s office (Lunshof
et al. 2008). The same holds true for clinical trials: they
differ in scale, but data are being shared and allow for
reidentification. Remaining silent on this point may cause
irrevocable damage to trust in science and researchers.
Indeed, study protocols and consent language increasingly
include paragraphs on data sharing.
Third, genotyping has become a service that is available
directly to consumers. Making use of these easy accessible
web-based services is a strictly individual decision, like the
purchase of any product or services via internet. However,
be it for genealogical, ancestry, or paternity testing, for
nutrigenomics or pharmacogenomics purposes, or suscep-
tibility testing for serious hereditary disorders, the client
hands over body material and personal information. Both
would be regarded as subject to strict confidentiality in the
patient–physician relationship.
Obviously, individuals, as patients or assumed healthy
consumers do have sufficient confidence in the standards of
confidentiality as advertised by the service providers. But,
being their own doctor you may get involved as well with
their course of action. This will often occur at the end,
when patients present you with the test results and seek
‘‘medical direction’’ (Hunter et al. 2008). However, you
might get involved at the beginning, as in our case, when a
patient asks you to be a facilitator of her decision to engage
in research that will make its yet unpredictable findings
available, together with previous medical data, not only to
herself but to an undefined research community, and in
open access studies also to the public at large.
In this new context, mutual trust is the basis for giving
up confidentiality and privacy protection. With blurring
boundaries between the clinical, the research, and the
commercial domain, the roles in the clinical encounter
likely need to be remodeled. Direct involvement of indi-
viduals in research, through interactive researcher–subject
communication may increase transparency and take a
burden off the patient–physician relationship. Modern
information technology has the tools for direct communi-
cation ready at hand. However, in a wired, web-based
world individuals should be aware that any personal data
that they release—informing about their lifestyle, opinions,
or health—may be used for drawing inferences that are
very detrimental to their lives. This may happen, regardless
of whether the data have been made available altruistically,
in good faith, or out of sheer naivety. Society can try to
regulate the use of health related and genetic data. But,
informing people of the potential impact of their own
decision to go public with their personal data will likely be
the first huge challenge beyond the traditional protection of
privacy and confidentiality.
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